Table 4. Properties of Inhibitory mAbs against Aggrecanasesa.
| mAb | format | target | epitope | KD (nM) | IC501 (nM) | ref |
|---|---|---|---|---|---|---|
| 7E8.1E3 | IgG | ADAMTS4 | Mp/Dis | 0.25 | 0.035 | (26) |
| 7C7.1H1 | IgG | ADAMTS4 | CR/Sp | 0.29 | 0.048 | (26) |
| GSK2394000 | IgG | ADAMTS5 | Mp/Dis | 0.21 | 11 | (26) |
| GSK2394002 | IgG | ADAMTS5 | Mp/Dis | 0.038 | 0.083 | (26) |
| 2B9 | scFc-Fv | ADAMTS5 | Sp | 6.6 | 90–140 | (27) |
| 2D3 | scFc-Fv | ADAMTS5 | Mp/Dis | 3.9 | 2.5 | (27) |
| 8–90 | (28) | |||||
| 1B7 | scFc-Fv | ADAMTS5 | Mp/Dis | 70 | NI | (29) |
| CRB0017 | IgG | ADAMTS5 | Sp | 2.2 | NR | (147) |
| 237-53 | Fab | ADAMTS4/ADAMTS5 | TS-1 | 12 (ADAMTS4) | 80 | (148) |
| 1.5 (ADAMTS5) | NR | |||||
| M6495 | Bivalent Nb | ADAMTS5 | Mp/Dis | 0.0037 | NR | (150) |
a
Values determined using aggrecan, Abbreviations: Nb, nanobody, single variable domain derived from heavy-chain-only antibodies of Camelidae; NI, not inhibiting; NR, not reported; scFv-Fc, single-chain variable fragment fused to the immunoglobulin crystallizable fragment.